home *** CD-ROM | disk | FTP | other *** search
- Path: sparky!uunet!zaphod.mps.ohio-state.edu!darwin.sura.net!udel!rochester!galileo.cc.rochester.edu!ub!netfs!dres.dnd.ca!jmcfee
- From: jmcfee@dres.dnd.ca (John McFee)
- Newsgroups: sci.med
- Subject: Use of DNase in cystic fibrosis therapy
- Keywords: cystic fibrosis DNase
- Message-ID: <1992Dec22.152810.9425@dres.dnd.ca>
- Date: 22 Dec 92 15:28:10 GMT
- Sender: news@dres.dnd.ca
- Reply-To: jmcfee@dres.dnd.ca
- Organization: Defence Research Establishment Suffield
- Lines: 21
- Nntp-Posting-Host: peregrin
-
- A year or so ago, there was big news about the use of inhaled DNase to
- thin out the mucous in the lungs of cystic fibrosis patients. Initial
- results were promising and so clinical trials had commenced (I'm not
- sure where).
-
- Recently I was talking to an MD from the Alberta Sick Childrens
- Hospital in Calgary. He said that the introduction of DNase therapy
- into general use had been delayed because some researchers had concerns
- that the breakdown products of Pseudomonas were more harmful than the
- Pseudomonas itself.
-
- Does anyone know the status of the clinical trials, the schedule for
- introduction of DNase into widespread use or anything about the
- reference to Pseudomonas. I have two 18 month old twin girls with CF,
- so naturally I'm a little concerned.
-
- Thanks!
-
- John Elton McFee --- Standard disclaimer.
- Threat Detection Group --- I speak for the trees
- DRE Suffield jmcfee@dres.dnd.ca --- For the trees have no tongues.
-